• 1
    Quinn M, Babb P, Brock A, Kirby E, Jones J. Cancer Trends in England and Wales 1950–1999. Studies on Medical and Population Subjects No. 66. London: Office for National Statistics, 2001.
  • 2
    Covens A, Carey M, Bryson P, Verma S, Fung K, Fung M, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002;85:7180.
  • 3
    Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001;6:10738.
  • 4
    Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:17682.
  • 5
    Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:10217.
  • 6
    Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol 1995;9:88793.
  • 7
    Trope CJ, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000;11:2818.
  • 8
    Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:10512.
  • 9
    Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for research and treatment of cancer–adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003;95:11324.
  • 10
    Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95:12532.
  • 11
    Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer (review). In: The Cochrane Library. 2009, issue 4. Published by John Wiley & Sons, Ltd [] Last accessed 10 June 2010.
  • 12
    Du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl 8):viii712.
  • 13
    Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102:4329.
  • 14
    National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V.2.2009 [] last accessed 10 June 2010.
  • 15
    Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:174856.
  • 16
    Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, et al. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six year experience of Hellenic Cooperative Oncology Group. BMC Cancer 2006;6:22835.
  • 17
    Shimada M, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Minagawa Y, et al. Outcomes of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging. Int J Gynecol Cancer 2005;15:6015.
  • 18
    Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK. Staging laparotomy in early ovarian cancer. J Am Med Assoc 1983;250:30726.
  • 19
    Fader AM, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:277383.
  • 20
    Argyriou A, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008;66:21828.
  • 21
    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:16.
  • 22
    Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699708.
  • 23
    The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:50515.
  • 24
    Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage iii or iv ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2000;18:10615.
  • 25
    du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:13209.